TB-500 Side Effects & Safety
What the Research Says
Introduction:
What are the side effects and safety concerns of TB-500?TB-500, a synthetic peptide fragment of thymosin β4, is used in research settings for its effects on tissue repair and recovery. While its benefits are well-documented in animal models, its safety and potential side effects—especially in humans—remain less clear.
Disclaimer: TB-500 is for laboratory research use only. It is not approved for human use, and all data discussed here comes from preclinical or investigational studies.
Known & Potential Side Effects
Summary Table: TB-500 Side Effects & Safety Data
Injection site irritation1
Anecdotal
Human (self-report)
Redness, minor pain
Headache, fatigue, mild nausea1
Uncommon, usually mild
Immune modulation23
Preclinical
Animal
No major immune suppression noted
Organ toxicity45
Not observed at standard doses
Carcinogenicity6
Animal, Cell
No evidence of tumor promotion
Allergic reactions
Extremely rare
Long-term effects
Unknown
N/A
No long-term human data available
References for Table
1.User anecdotal reports on peptide forums (no peer-reviewed clinical trials)
2.Goldstein AL et al. Mol Biol Cell. 1992;3(9):1015–1024.
3.Sosne G et al. Ann N Y Acad Sci. 2007;1112:232–240.
4.Bock-Marquette I et al. J Biol Chem. 2010;285(51):39345–39354.
5.Stewart DJ et al. Circ Res. 2012;111(7):940–950.
6.Fan J et al. Front Endocrinol (Lausanne). 2021;12:767785.
Preclinical Safety & Toxicology
Animal studies: TB-500 has been tested at a range of doses (2–10 mg/kg daily), with no evidence of organ toxicity, immune suppression, or carcinogenicity at these levels24.
High-dose testing: Studies using higher-than-research doses still did not reveal acute toxicity or significant adverse effects45.
Immune effects: Most preclinical research finds no major effect on white blood cell counts, antibody response, or overall immune system function23.
Tumor risk: No preclinical evidence suggests TB-500 increases cancer risk or accelerates tumor growth6.
Human Data: Clinical Trials & Anecdotes
Clinical trial data: Most human safety data comes from studies of full-length thymosin β4, not TB-500 itself. These studies (for wound and eye healing) reported no significant adverse effects at tested doses3.
Anecdotal reports: Minor injection site reactions (redness, pain) and occasional headache or nausea are the most commonly reported side effects on peptide forums. These are not validated by clinical research.
Long-term effects: There are currently no published studies evaluating long-term, high-dose, or chronic use of TB-500 in humans.
Uncertainties, Compliance, & Best Practices?
For research use only: TB-500 is not FDA-approved for any therapeutic purpose.
Limitations: Most side effect data comes from animal studies and user anecdotes, not controlled human trials.
Use the lowest effective dose
Monitor for unexpected reactions
Record all adverse events, even if mild
Strictly label all materials as “research use only”
Frequently Asked Questions (FAQs)
What are the most common side effects of TB-500?
Minor injection site irritation is the most frequently reported, along with rare cases of headache or nausea (mostly from anecdotal user reports).
Is TB-500 safe in animal studies?
At typical research doses, animal studies have found no evidence of acute or chronic toxicity, organ damage, or tumor formation.
Are there any known risks of long-term TB-500 use?
There are no published studies on long-term human use; safety beyond short-term, low-dose research is unknown.
Is TB-500 immunosuppressive?
Preclinical data does not show significant immune suppression at research doses.
Can TB-500 cause cancer?
No evidence exists in preclinical studies that TB-500 increases cancer risk.